Comparative Pharmacology
Head-to-head clinical analysis: FORTESTA versus TESTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTESTA versus TESTIM.
FORTESTA vs TESTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
Testosterone replacement therapy; binds to and activates androgen receptors, modulating gene expression leading to male sexual development and maintenance of secondary sexual characteristics.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
Apply 5 g (1 tube) of 1% gel to clean, dry, intact skin of the shoulders, upper arms, or abdomen once daily, preferably in the morning. Dosage may be adjusted to 10 g (2 tubes) depending on clinical response. Apply immediately after opening and avoid bathing or swimming for at least 30 minutes.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Terminal elimination half-life of testosterone from serum is approximately 10-100 minutes after intravenous administration, but after transdermal application of Testim, the apparent half-life is longer (around 1-2 hours) due to continued absorption from the skin depot. The half-life of active metabolites (e.g., dihydrotestosterone) is about 2-3 hours.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Category C
Category C
Androgen
Androgen